Evestia Clinical has merged with Atlantic Research Group (ARG), a US-based CRO, to create a leading independent global specialist CRO group in fast-growing markets.
The merger expands Evestia Clinical’s global footprint in the US and broadens its therapeutic and services offering to include neurology and late-stage clinical trial services.
The enlarged group also provides access to enhanced technologies to further meet the tailored needs of its clients.
Evestia Clinical’s highly experienced board and leadership team has a strong track record of building market-leading mid-tier CROs with a reputation for operational excellence and outstanding service delivery.
The combination with ARG is further evidence of the Company’s ambitions to rapidly grow its offering and services to customers around the world.
The deal immediately more than doubles the size of the Group by headcount and service delivery capability.
In turn, ARG’s clients will benefit from a seamless transition to Evestia Clinical, with immediate access to its global presence and capabilities, including new areas of therapeutic expertise, such as rare diseases.
Richard Barfield, Chairman of Evestia Clinical, said: “Evestia Clinical was founded to rapidly build a global specialist CRO through organic and acquisitive growth. The Evestia Clinical board and leadership team identified ARG as the perfect company to combine with at this stage in our journey."
"The reputation of ARG’s leadership team and its high-quality CRO offering is widely recognised within the biotech and specialty pharma industry, and we are excited that they have chosen to grow with us as part of the Evestia Clinical group.”
Following the merger, the combined Group will provide a full suite of clinical trial services across the development lifecycle from Phase I to Phase III and beyond.
The Group’s combined technologies will enhance its ability to deliver specialised services to clients across a range of therapeutic areas.
Lewis Cameron, CEO of Evestia Clinical, said: “We’re incredibly excited to be joining forces with ARG as we accelerate our journey to build Evestia Clinical into a leading mid-tier specialist CRO with a truly global reach."
"The combined Group will immediately provide benefits for our clients, and I look forward to working with Paul, Lyle and the broader ARG team as we grow Evestia Clinical together and deliver the highest quality services to clients worldwide.”
Paul Bishop, CEO of ARG, and Lyle Camblos, President of ARG, said: “In Evestia Clinical and Kester Capital, ARG has found the ideal and trusted partner for our next stage of growth."
"The highly experienced and globally recognised leadership team at Evestia Clinical is building a world-class specialist CRO provider and we are excited to bring across our whole team on this journey."
"We are pleased that our customers will be able to benefit from this seamless continuity as well as the combined Group’s enhanced capabilities.”
Terms of the deal have not been disclosed. Following the merger, ARG will integrate with Evestia Clinical’s operations with no change to its services or teams.
The ARG leadership team will join the senior leadership team of the enlarged Group to support future growth and expansion.
All employees are expected to transition as part of the agreement.
Evestia Clinical will be headquartered in the UK in Letchworth and in the US in Charlottesville, VA, with global capabilities through its network of offices, CRO professionals and expert partners.
